Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8989544 | 0.94 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL8990003 | 0.90 | DRD2 (0.40) | SMN1; SMN2NPC1RAB9AGPBAR1 | |
| SCHEMBL13525373 | 0.90 | SLC6A4 (0.36) | SMN1; SMN2NPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL8989307 | 0.84 | HPGD (0.38) | SMN1; SMN2NPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL8988738 | 0.83 | LMNA (0.42) | SMN1; SMN2NPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL2391310 | 0.83 | HTT (0.40) | SMN1; SMN2NPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL8989511 | 0.83 | MAPT (0.42) | RAB9AMGLL | |
| SCHEMBL8989514 | 0.83 | MAPT (0.42) | RAB9AMGLL | |
| SCHEMBL8989848 | 0.80 | RAB9A (0.43) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14233833 | 0.78 | ALDH1A1 (0.39) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188279-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110237797-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237797-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | SMN1; SMN2 2355/4885NPC1 609/4885RAB9A 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.